Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$51.1K Hold
1,820
0.03% 52
2025
Q4
$45.3K Hold
1,820
0.02% 51
2025
Q3
$46.4K Hold
1,820
0.03% 48
2025
Q2
$44.1K Sell
1,820
-2,166
-54% -$50.5K 0.03% 42
2025
Q1
$101K Buy
3,986
+293
+8% +$7.67K 0.08% 25
2024
Q4
$98K Buy
3,693
+3,277
+788% +$88.9K 0.08% 23
2024
Q3
$12K Hold
416
0.01% 60
2024
Q2
$11.6K Hold
416
0.01% 58
2024
Q1
$11.5K Hold
416
0.01% 58
2023
Q4
$12K Hold
416
0.01% 51
2023
Q3
$13.8K Hold
416
0.03% 46
2023
Q2
$15.3K Hold
416
0.04% 40
2023
Q1
$17K Hold
416
0.07% 35
2022
Q4
$21.3K Hold
416
0.04% 33
2022
Q3
$18K Hold
416
0.03% 33
2022
Q2
$21K Hold
416
0.06% 29
2022
Q1
$21K Hold
416
0.02% 37
2021
Q4
$24K Buy
+416
New +$20.6K 0.02% 46
2021
Q1
Sell
-916
Closed -$33K 113
2020
Q4
$33K Buy
+916
New +$33.6K 0.03% 57

Other funds holding PFE

IFS Advisors's PFE Position: Q1 2026 in Review

IFS Advisors held its Pfizer (PFE) position steady in Q1 2026 at 1,820 shares worth $51.1K. The position accounts for 0.03% of the portfolio, ranked #52.

IFS Advisors first reported a position in PFE in Q4 2020 and has held it in 19 quarters since. The position peaked at $101K in Q1 2025. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • IFS Advisors held 1,820 shares of Pfizer worth $51.1K as of Q1 2026.
  • IFS Advisors left its Pfizer share count unchanged in Q1 2026.
  • Pfizer made up 0.03% of IFS Advisors's portfolio in Q1 2026, its #52 holding.
  • IFS Advisors first reported a position in Pfizer in Q4 2020 and has held it in 19 quarters since.
  • IFS Advisors's Pfizer position peaked at $101K in Q1 2025.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on IFS Advisors's 13F filing for Q1 2026, filed 6 Apr 2026.